Udai Banerji

12.1k citations

207 papers · 7.4k indexed · 4 hit papers · h-index 40

Oncology top 1%
- Colorectal Cancer Treatments and Studies 25
- Cancer Treatment and Pharmacology 22
Cancer Research top 1%
- Cancer Genomics and Diagnostics 41
Molecular Biology top 1%
- PI3K/AKT/mTOR signaling in cancer 36
- Melanoma and MAPK Pathways 18
- Heat shock proteins research 18
Radiology, Nuclear Medicine and Imaging top 2%
Immunology top 5%
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 28
- Advanced Breast Cancer Therapies 16

Co-authors: Paul Workman Bissan Al‐Lazikani Nikolaos Diamantis Juanita Lopez Ian Judson Johann S. de Bono Susana Banerjee Elena Cojocaru
Cited by: Oncology Cancer Research Molecular Biology
Journals: Nature Communications (1 paper)Journal of Clinical Oncology (52 papers)SHILAP Revista de lepidopterología (1 paper)
Partner nations: United Kingdom United States Canada

In The Last Decade

Udai Banerji

195 papers receiving 7.3k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2020 Nature Reviews Clinical Oncology
2019 The Lancet Oncology
2016 British Journal of Cancer
2012 Nature Biotechnology

Peers

Countries citing papers authored by Udai Banerji

Since Specialization

Citations

This map shows the geographic impact of Udai Banerji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Udai Banerji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Udai Banerji more than expected).

Fields of papers citing papers by Udai Banerji

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Udai Banerji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Udai Banerji. The network helps show where Udai Banerji may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Udai Banerji, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Udai Banerji Line = papers co-authored together Udai Banerji links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Proteomic Landscapes of 3D and 2D Models of High-Grade Serous Ovarian Carcinoma: Implications for Carboplatin Response Journal of Proteome Research ·Julien Maillard,Theodoros I. Roumeliotis,Ekta Paranjape,Lisa Pickard,Alvaro Ingles Garces,Jyoti S. Choudhary,Udai Banerji	2025	0
2	85P: Phase I results from the phase I/II POTENT trial of tepotinib and pembrolizumab in non-small cell lung cancer (NSCLC) Journal of Thoracic Oncology ·K-L. Koster,A.S.D.F.M. Parreira,Harold Nathan Tan,Athanasios Zachariou,O. Faboyede,Sudhir Venkatesan,M. Parmar,Bindumalini Rao Baikady,Xiaolin Hu,Ruth Ruddle,Christina Yap,Marie Forster,S. Popat,Juanita Lopez,Johann S. de Bono,A. Sharp,Udai Banerji,A. Paschalis,Charlotte Lindsay,Anna Minchom	2025	0
3	First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors Clinical Cancer Research ·Robert McLeod,Rajiv Kumar,Dionysis Papadatos-Pastos,Joaquı́n Mateo,Jessica Brown,Alvaro Ingles Garces,Ruth Ruddle,Shaun Decordova,Simone Jueliger,Roberta Ferraldeschi,Óscar Maiques,Victoria Sanz‐Moreno,Paul S. Jones,Stephanie Traub,Gavin Halbert,Sarah Mellor,Karen E. Swales,Florence I. Raynaud,Michelle D. Garrett,Udai Banerji	2020	52
4	Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials Clinical Cancer Research ·Angelika Terbuch,Crescens Tiu,Irene Moreno Candilejo,Mariana Scaranti,Andra Curcean,Dan Bar,Miriam Estevez Timon,Malaka Ameratunga,Joo Ern Ang,Jonathan Ratoff,Anna Minchom,Udai Banerji,Johann S. de Bono,Nina Tunariu,Juanita Lopez	2020	13
5	Inactivation of NF1 Promotes Resistance to EGFR Inhibition in KRAS/NRAS/BRAFV600 -Wild-Type Colorectal Cancer Molecular Cancer Research ·Alexandros Georgiou,Adam Stewart,David Cunningham,Udai Banerji,Steven R. Whittaker	2020	19
6	Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS -Mutant Cancers Molecular Cancer Therapeutics ·Adam Stewart,Elizabeth A. Coker,Sebastian Pölsterl,Alexandros Georgiou,Anna Minchom,Suzanne Carreira,David Cunningham,Mary O’Brien,Florence I. Raynaud,Johann S. de Bono,Bissan Al‐Lazikani,Udai Banerji	2019	14
7	Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma Molecular Cancer Therapeutics ·Joo Ern Ang,Ákos Pál,Yasmin J. Asad,Alan T. Henley,Melanie Valenti,Gary Box,Alexis de Haven Brandon,Victoria L. Revell,Debra J. Skene,Miro Venturi,Ruediger Rueger,Valérie Méresse,Suzanne A. Eccles,Johann S. de Bono,Stanley B. Kaye,Paul Workman,Udai Banerji,Florence I. Raynaud	2017	8
8	Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic? Clinical Cancer Research ·Desamparados Roda,Begoña Jiménez,Udai Banerji	2015	20
9	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014 Clinical Cancer Research ·Bristi Basu,Emma Dean,M. Puglisi,Alastair Greystoke,Michael Ong,Wendy Burke,Maria Cavallin,Graham Bigley,Christopher J. Womack,Elizabeth A. Harrington,Stephen Green,Elisabeth Oelmann,Johann S. de Bono,Malcolm Ranson,Udai Banerji	2015	102
10	Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials Clinical Cancer Research ·Saeed Rafii,Desamparados Roda,Elena Geuna,Begoña Jiménez,Karim Rihawi,Marta Capelán,Timothy A. Yap,L. Rhoda Molife,Stanley B. Kaye,Johann S. de Bono,Udai Banerji	2015	28
11	89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients Clinical Cancer Research ·Sietske B.M. Gaykema,Carolien P. Schröder,Joanna Vitfell-Rasmussen,Sue Chua,Thijs H. Oude Munnink,Adrienne H. Brouwers,Alfons H.H. Bongaerts,Mikhail Akimov,Cristina Fernandez‐Ibarra,Marjolijn N. Lub–de Hooge,Elisabeth G.E. de Vries,Charles Swanton,Udai Banerji	2014	95
12	First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer Clinical Cancer Research ·Sarah P. Blagden,Aurelius Olmin,Debra H. Josephs,Chara Stavraka,Andrea Zivi,David J. Pinato,Alan Anthoney,Shaun Decordova,Karen E. Swales,Ruth Riisnaes,Lorna Pope,Kohei Noguchi,Rie Shiokawa,Michiyasu Inatani,Jenny Prince,Keith Jones,Chris Twelves,James Spicer,Udai Banerji	2014	36
13	First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors Clinical Cancer Research ·Cristiana Sessa,Geoffrey I. Shapiro,Kapil N. Bhalla,Carolyn D. Britten,Karen S. Jacks,Monica Mita,Vali Papadimitrakopoulou,Tim Pluard,Thomas A. Samuel,Mikhail Akimov,Cornelia Quadt,Cristina Fernandez‐Ibarra,Hong Lü,Stuart Bailey,Sandra Chica,Udai Banerji	2013	119
14	A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors Clinical Cancer Research ·Balaji Venugopal,Richard D. Baird,Rebecca Kristeleit,Ruth Plummer,Richard Cowan,Adam Stewart,Nele Fourneau,Peter Hellemans,Yusri Elsayed,Steve Mcclue,Johan W. Smit,Ann Forslund,Charles E. Phelps,A. John Camm,T.R. Jeffry Evans,Johann S. de Bono,Udai Banerji	2013	97
15	The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer Molecular Cancer Therapeutics ·Craig P. Carden,Adam Stewart,Parames Thavasu,Emma Kipps,Lorna Pope,Mateus Crespo,Susana Miranda,Gerhardt Attard,Michelle D. Garrett,Paul A. Clarke,Paul Workman,Johann S. de Bono,Martin Gore,Stan B. Kaye,Udai Banerji	2012	81
16	First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors Clinical Cancer Research ·Maria Martinez‐García,Udai Banerji,Joan Albanell,Rastilav Bahleda,Saoirse Dolly,Françoise Kraeber‐Bodéré,Federico Rojo,Émilie Routier,Ernesto Guarin,Zhixin Xu,Ruediger Rueger,Jean Tessier,Eliezer Shochat,Steve Blotner,Valérie Meresse Naegelen,Jean‐Charles Soria	2012	122
17	A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors Clinical Cancer Research ·Udai Banerji,Leni van Doorn,Dionysis Papadatos-Pastos,Rebecca Kristeleit,Phillip Debnam,Matthew Tall,Adam Stewart,Florence I. Raynaud,Michelle D. Garrett,Martin Toal,Leon Hooftman,Johann S. de Bono,Jaap Verweij,Ferry A.L.M. Eskens	2012	64
18	A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors Clinical Cancer Research ·Simon Pacey,Richard H. Wilson,Mike Walton,Martin Eatock,Anthea Hardcastle,Anna Zetterlund,Hendrik‐Tobias Arkenau,Javier Moreno‐Farre,Udai Banerji,Belle Roels,Heidi Peachey,Wynne Aherne,Johann S. de Bono,Florence I. Raynaud,Paul Workman,Ian Judson	2011	154
19	The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer Clinical Cancer Research ·Udai Banerji,D. Ross Camidge,Henk M.W. Verheul,Roshan Agarwal,Debashis Sarker,Stan B. Kaye,Ingrid M.E. Desar,Johanna N.H. Timmer-Bonte,Sabine Eckhardt,Karl D. Lewis,Kathryn H. Brown,Mireille Cantarini,Clive Morris,Sarah M.A. George,Paul D. Smith,Carla M.L. van Herpen	2010	176
20	Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models Clinical Cancer Research ·Udai Banerji,Michael I. Walton,Florence I. Raynaud,Rachel Grimshaw,Lloyd R. Kèlland,Melani Valenti,Ian Judson,Paul Workman	2005	126

About Udai Banerji

Udai Banerji is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 207 papers that have together received 7.4k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (41 papers), PI3K/AKT/mTOR signaling in cancer (36 papers), Lung Cancer Treatments and Mutations (28 papers), Colorectal Cancer Treatments and Studies (25 papers), Cancer Treatment and Pharmacology (22 papers), Melanoma and MAPK Pathways (18 papers), Heat shock proteins research (18 papers) and Advanced Breast Cancer Therapies (16 papers). The work is most often cited by research in Oncology (2.7k citations), Cancer Research (1.2k citations) and Molecular Biology (4.3k citations). Udai Banerji has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include Paul Workman, Bissan Al‐Lazikani, Nikolaos Diamantis, Juanita Lopez, Ian Judson, Johann S. de Bono, Susana Banerjee, Elena Cojocaru, Mariana Scaranti and Jessica Brown. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact